Tiefengraber E, Sebesta C, Kier P, Ruckser R, Habertheuer K H, Hinterberger W
Ludwig-Boltzmann-Institut für Stammzelltransplantation, Wien.
Wien Med Wochenschr. 1995;145(2-3):50-2.
Autologous bone marrow transplantation (ABMT) performed with recent achievements plays yet no established role in the treatment of small cell lung cancer (SCLC). The majority of treatment results obtained so far do not clearly suggest a superiority of high-dose therapy with autologous transplantation over conventional polychemo/radiotherapy. It is unknown, whether or not a subgroup of patients with, e.g., "limited disease" and chemosensitive tumor may benefit from ABMT. Randomized trials will be necessary to clarify this question.
近期开展的自体骨髓移植（ABMT）在小细胞肺癌（SCLC）治疗中尚未发挥既定作用。迄今为止获得的大多数治疗结果并未明确显示自体移植高剂量疗法优于传统的多化疗/放疗。例如，患有“局限性疾病”且肿瘤对化疗敏感的患者亚组是否能从ABMT中获益尚不清楚。有必要通过随机试验来阐明这个问题。
